Antipsychotic and Anxiolytic Properties of Risperidone, Haloperidol, and Methotrimeprazine in Schizophrenic

Journal of Clinical Psychopharmacology

Volumn 16, Issue 1, 1996, Pages 38-44

  Blin, Olivier ^a   Azorin, Jean Michel ^a   Bquhours, Philippe ^b  

^a TIMONE HOSPITAL   (France)

^b Laboratoires Janssen   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; LEVOMEPROMAZINE; RISPERIDONE;

ADULT; AKATHISIA; ANXIETY; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HYPOTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; XEROSTOMIA;

ADOLESCENT; ADULT; ANTI-ANXIETY AGENTS; ANTIPSYCHOTIC AGENTS; ANXIETY; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; FEMALE; HALOPERIDOL; HUMANS; MALE; METHOTRIMEPRAZINE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0030067199     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199602000-00007     Document Type: Article

References (21)

1. Seeman P. Dopamine receptors and the dopamme hypothesis of schizophrenia, Synapse 1987;1:133-52.
2. Woolley DW, Shaw E. A biochemical and pharmacological suggestion about certain mental disorders. Proc Natl Acad Sci 1954;40:228-31.
3. Gelders YG. Thymostenic agents: a novel approach in the treatment of schizophrenia. Br J Psychiatry 1989;155 [suppl]:33-6.
4. Ereshefsky L, Watanabe MD, Tran-Johnson TK. Clozapine: an atypical antipsychotic agent. Clin Pharm 1989;8:691-709.
5. Kane J, Honigfeld G, Singer J, Meltzer HY. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 1988;45:789-96.
6. Lieberman J, Alvir J. A report of clozapine-induced agranulocytosis in the United States. Drug Saf 1992;7[suppl]:1-2.
7. Cohen LJ. Risperidone. Pharmacotherapy 1994;14:253-65.
8. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40.
9. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-35.
10. Lambert PA, Revol L. Classification psychopharmacologique et clinique des différents neuroleptiques. Presse Med 1960;60:1509-11.
11. 2 receptors. Psychopharmacologia 1993;112[suppl]:S40-S54.
12. Bun O, Lecrubier Y, Azorin JM, Souche A, Fondarai J. Construction et étude préliminaire de validation d'une échelle originale d'évaluation de l'anxiété chez le psychotique: le PAS (Psychotic Anxiety Scale), Psychiatry & Psychobiol 1988;3:255-61.
13. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia Schizophr Bull 1987;13:261-76.
14. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812.
15. Guy W, ed. ECDEU assessment manual for psyehopharmacology. Publication ADM 76-338. Washington, DC: US Department of Health, Education, and Welfare, 1976.
16. Blin O, Azorin JM, Lecrubier Y, Souche A, Fondarai J. Psychotic Anxiety Scale (PAS): Évaluation de la fidelité intercotateurs et analyse factorielle des correspondances. Encephale 1989;15:543-47.
17. Chouinard G, Ross-Chouinard A, Annable L, Jones BD. Extrapyramidal Symptom Rating-Scale. Can J Neurol Sci 1980;7:233.
18. Åsberg M, Cronholm B, Sjöckvist F, Tuck D. Correlation of subjective side effects with plasma concentrations of nortriptyline. Br Med J 1970;4:18-21.
19. Reynolds JEF, ed. Martindale: the extra pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993.
20. Borison RL, Pathiraja AP, Diamond BI, Meibach RC. Risperidone: clinical safety and efficacy in schizophrenia Psychopharmacol Bull 1992;28:213-8.
21. Kapsambelis V, Gekiere C, Ginestet D. Classifications cliniques des neuroleptiques: étude critique et perspectives actuelles. Encephale 1990;16:63-70.